| Symbol | CBPHF |
|---|---|
| Name | CLOVER BIOPHARMACEUTICALS LTD. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | China Room 1901, No. 758 West Nanjing Road Jing’an District |
| Telephone | — |
| Fax | — |
| — | |
| Website | https://www.cloverbiopharma.com/ |
| Incorporation | KY |
| Incorporated On | 2018 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Hong Kong Stock Exchange |
| CIK | 0001856491 |
| Description | Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The companys product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; and SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia. It is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment. In addition, the company sells biopharmaceutical drugs. Additional info from OTC: |
No news found.